Base to Base biotech podcast 50: Drugs for kidney transplants, glycans, and  drug delivery
Anti-cancer drug gets phase I FDA trials approval
New mass spec platform launched
Approval for prostate cancer treatment
Fast-acting actin explains the survival of cancer cells
Phase 2 data for chronic inducible urticaria
Base to Base biotech podcast 28: CTPS1 and ocular therapeutics
Positive results from phase 1 Huntington’s disease trial
Potential for drug targeting BDCA2 and TACI
CCHF in the crosshairs
Kalexo Bio formed to advance siRNA therapy for cardiovascular disorders
First liquid ambient temperature stable qPCR master mixes